a month ago
EYPT
AnalystsAndreas ArgyridesAndreas Argyrides's Stock Forecasts
AnalystsAndreas Argyrides
Sectors:
Analyst Ranking
Top 8%
#436 out of 5487 analysts
Average Return
+19.56%
Win Rate
51%61 out of 119
Risk vs Reward
Poor
Good
Andreas Argyrides's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Aquestive Therapeutics IncAQST | +502.47% | $0.81 | $4.88 | 2023-03-09 - 2024-03-08 | Buy |
Regulus Therapeutics IncRGLS | +429.87% | $1.54 | $8.16 | 2024-08-14 - 2025-06-24 | Buy |
Ars Pharmaceuticals IncSPRY | +315.25% | $4.00 | $16.61 | 2023-11-13 - 2024-11-12 | Buy |
Ars Pharmaceuticals IncSPRY | +302.45% | $3.67 | $14.77 | 2023-09-21 - 2024-09-20 | Buy |
Aquestive Therapeutics IncAQST | +240.00% | $1.40 | $4.76 | 2023-10-10 - 2024-10-09 | Buy |
Andreas Argyrides Analyst Color
Get additional color on Andreas Argyrides's coverage of popular stocks
2 months ago
IRD
Andreas Argyrides's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Eyepoint IncEYPT | 2 | Strong Buy | $65.00 | +397.32% | Maintains | 4 days ago |
Ocular Therapeutix IncOCUL | 2 | Strong Buy | $23.00 | +148.92% | Maintains | 7 days ago |
Opus Genetics IncIRD | 3 | Strong Buy | $13.00 | +255.19% | Maintains | a month ago |
Liquidia CorpLQDA | 8 | Sell | $19.00 | -79.13% | Maintains | 5 months ago |
Gossamer Bio IncGOSS | 9 | Buy | $3.00 | +1,604.55% | Maintains | 5 months ago |
United Therapeutics CorpUTHR | 2 | Buy | $600.00 | +13.28% | Maintains | 6 months ago |
Moonlake ImmunotherapeuticsMLTX | 15 | Buy | $35.00 | +101.96% | Maintains | 6 months ago |
Evommune IncEVMN | 1 | Buy | $42.00 | +198.51% | Initiates Coverage On | 7 months ago |
Dyne Therapeutics IncDYN | 5 | Buy | $40.00 | +50.94% | Upgrades | 8 months ago |
Savara IncSVRA | 2 | Buy | $9.00 | +57.07% | Maintains | 9 months ago |
Keros Therapeutics IncKROS | 9 | Buy | $27.00 | +152.57% | Reiterates | 9 months ago |
Monopar TherapeuticsMNPR | 2 | Buy | $115.00 | -1.16% | Maintains | 10 months ago |
Larimar Therapeutics IncLRMR | 2 | Buy | $21.00 | +423.69% | Maintains | 10 months ago |
Benitec Biopharma IncBNTC | 2 | Buy | $29.00 | +110.45% | Maintains | a year ago |
Kala Bio IncKALA | 2 | Buy | $1,650.00 | +218,443.05% | Maintains | a year ago |
Mannkind CorpMNKD | 2 | Buy | $15.00 | +281.68% | Maintains | a year ago |
Abeona Therapeutics IncABEO | 2 | Buy | $20.00 | +168.46% | Maintains | a year ago |
Harmony Biosciences Holdings IncHRMY | 1 | Buy | $61.00 | N/A | Assumes | a year ago |
Aquestive Therapeutics IncAQST | 5 | Buy | $7.00 | N/A | Assumes | a year ago |
Inflarx NvIFRX | 2 | Buy | $3.00 | N/A | Maintains | a year ago |
Rani Therapeutics Holdings IncRANI | 5 | Buy | $4.00 | N/A | Maintains | a year ago |
Korro Bio IncKRRO | 1 | Buy | $90.00 | N/A | Maintains | a year ago |
Proqr Therapeutics NvPRQR | 1 | Buy | $9.00 | N/A | Maintains | a year ago |
Ascendis Pharma AASND | 9 | Buy | $181.00 | N/A | Reiterates | 2 years ago |
Regulus Therapeutics IncRGLS | 1 | Buy | $7.00 | N/A | Reiterates | 2 years ago |
Clearside Biomedical IncCLSDQ | 1 | Buy | $75.00 | N/A | Initiates Coverage On | 2 years ago |
Ars Pharmaceuticals IncSPRY | 9 | Buy | $19.00 | N/A | Reiterates | 2 years ago |
Oculis Holding AgOCS | 3 | Buy | $29.00 | N/A | Reiterates | 2 years ago |
Regenxbio IncRGNX | 4 | Hold | $21.00 | N/A | Reiterates | 2 years ago |
Sarepta Therapeutics IncSRPT | 4 | Buy | $224.00 | N/A | Reiterates | 2 years ago |
Pacira Biosciences IncPCRX | 2 | Buy | $57.00 | N/A | Reiterates | 3 years ago |
Immunic IncIMUX | 3 | Buy | $70.00 | N/A | Maintains | 3 years ago |
Sangamo Therapeutics IncSGMO | 3 | Buy | $10.00 | N/A | Maintains | 3 years ago |
Biomarin Pharmaceutical IncBMRN | 6 | Hold | $70.00 | N/A | Maintains | 3 years ago |
Unity Biotechnology IncUNBX | 4 | Hold | $2.00 | N/A | Downgrades | 3 years ago |
Albireo Pharma IncALBO | 2 | Hold | $42.00 | N/A | Downgrades | 4 years ago |
Global Blood Therapeutics IncGBT | 1 | Hold | N/A | N/A | Downgrades | 4 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.